SIRT2 Antibodies

Target Information

an NAD-dependent protein deacetylase. Deacetylates internal lysines on histone and alpha-tubulin as well as many other proteins such as key transcription factors and metabolic enzymes. Histone deacetylation is generally associated with transcriptional repression. Associates both with chromatin at transcriptional start sites (TSSs) and enhancers of active genes. Plays a role in cell cycle and chromatin compaction through epigenetic modulation of the regulation of histone H4 'Lys-20' methylation (H4K20me1) during early mitosis. Deacetylates histone H4 at 'Lys-16' (H4K16ac) at the VEGFA promoter and thereby contributes to regulate expression of VEGFA, a key regulator of angiogenesis. Deacetylates 'Lys-40' of alpha-tubulin. Involved in the control of mitotic exit in the cell cycle, probably via its role in the regulation of cytoskeleton. Deacetylates PCK1, opposing proteasomal degradation. Deacetylates 'Lys-310' of RELA. Interacts with HDAC6, suggesting that these proteins belong to a large complex that deacetylate the cytoskeleton. Plays a role in the regulation of blood glucose homeostasis by deacetylating and stabilizing phosphoenolpyruvate carboxykinase PCK1 activity in response to low nutrient availability. Acts as a key regulator in the pentose phosphate pathway (PPP) by deacetylating and activating the glucose-6-phosphate G6PD enzyme, and therefore, stimulates the production of cytosolic NADPH to counteract oxidative damage. Maintains energy homeostasis in response to nutrient deprivation as well as energy expenditure by inhibiting adipogenesis and promoting lipolysis. Widely expressed. Highly expressed in heart, brain and skeletal muscle, while it is weakly expressed in placenta and lung. Weakly expressed in several malignancies including breast, liver, brain, kidney and prostate cancers compared to normal tissues. Weakly expressed in glioma cell lines compared to normal brain tissues. Down-regulated in many gliomas suggesting that it may act as a tumor suppressor gene in human gliomas possibly through the regulation of microtubule network. Five alternatively spliced human isoforms have been reported. Isoform 1: Deacetylates EP300, alpha-tubulin and histone H3 and H4. Isoform 2: Deacetylates EP300, alpha-tubulin and histone H3 and H4. Isoform 5: Lacks deacetylation activity. Widely expressed. Highly expressed in heart, brain and skeletal muscle, while it is weakly expressed in placenta and lung. Isoform 1 is expressed in heart, liver and skeletal muscle, weakly expressed in the cortex. Isoform 2 is strongly expressed in the cortex, weakly expressed in heart and liver. Inhibited by Sirtinol, A3 and M15 small molecules. Inhibited by nicotinamide.Belongs to the sirtuin family. Class I subfamily. Note: This description may include information from UniProtKB.

Alternate Names

NAD-dependent deacetylase sirtuin-2; NAD-dependent protein deacetylase sirtuin-2; Regulatory protein SIR2 homolog 2; silencing information regulator 2-like; silent information regulator 2; SIR2; SIR2-like protein 2; sir2-related protein type 2; SIR2L; SIR2L2; SIRT2; sirtuin (silent mating type information regulation 2 homolog) 2 (S. cerevisiae); sirtuin 2; sirtuin type 2